According to US-FDA, its ‘Import Bans’ on quality grounds of the drugs manufactured at various Indian facilities, such as, Ranbaxy’s Paonta Sahib, Dewas and Mohali and Toansa plants, were reportedly solely directed at negating the health safety risks of American patients … Continue reading
Big Pharma’s Windfall Gain From Indian Pharma’s Loss, Costs American Patients Dear
Reply